Mediators of Inflammation / 2014 / Article / Tab 4

Research Article

Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial

Table 4

Metabolic parameters at baseline (J0) and after 12 weeks (M3) of placebo or statin treatment.

J0M3Change M3 − J0 Difference in change (95% CI)

Total cholesterol (g/L)
 Placebo ()−0.89 (−1.50; −0.27)
 Statin ()$§£
LDL cholesterol (g/L)
 Placebo ()−0.65 (−0.96; −0.34)
 Statin ()
HDL cholesterol (g/L)
 Placebo ()−0.31 (−0.78; 0.17)
 Statin ()
Triglycerides (g/L)
 Placebo ()0.09 (−0.27; 0.46)
 Statin ()
Glycemia (mmol/L)
 Placebo ()0.06 (−0.34; 0.46)
 Statin ()
Insulinemia (mUI/L)
 Placebo ()−2.27 (−8.96; 4.42)
 Statin ()
HOMA
 Placebo ()−0.66 (−2.83; 1.51)
 Statin ()
Hemoglobin A1c (%)
 Placebo ()0.04 (−0.12; 0.19)
 Statin ()

Data are mean ± SD. LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA, homeostasis model assessment of insulin resistance.
$ for value group, § value visit, £ value interaction, by repeated measure two-way ANOVA, followed by a Bonferroni post hoc test when necessary.